![](/img/cover-not-exists.png)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Park, Keunchil, Tan, Eng-Huat, O'Byrne, Ken, Zhang, Li, Boyer, Michael, Mok, Tony, Hirsh, Vera, Yang, James Chih-Hsin, Lee, Ki Hyeong, Lu, Shun, Shi, Yuankai, Kim, Sang-We, Laskin, Janessa, Kim, Dong-Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(16)30033-X
Date:
April, 2016
File:
PDF, 524 KB
english, 2016